These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
401 related articles for article (PubMed ID: 17983259)
61. Long-term retention on treatment with lumiracoxib 100 mg once or twice daily compared with celecoxib 200 mg once daily: a randomised controlled trial in patients with osteoarthritis. Fleischmann R; Tannenbaum H; Patel NP; Notter M; Sallstig P; Reginster JY BMC Musculoskelet Disord; 2008 Mar; 9():32. PubMed ID: 18328090 [TBL] [Abstract][Full Text] [Related]
62. Aldosterone glucuronidation inhibition as a potential mechanism for arterial dysfunction associated with chronic celecoxib and diclofenac use in patients with rheumatoid arthritis. Crilly MA; Mangoni AA; Knights KM Clin Exp Rheumatol; 2013; 31(5):691-8. PubMed ID: 23899748 [TBL] [Abstract][Full Text] [Related]
63. The hepatic safety and tolerability of the cyclooxygenase-2 selective NSAID celecoxib: pooled analysis of 41 randomized controlled trials. Soni P; Shell B; Cawkwell G; Li C; Ma H Curr Med Res Opin; 2009 Aug; 25(8):1841-51. PubMed ID: 19530981 [TBL] [Abstract][Full Text] [Related]
64. Gastrointestinal safety of amtolmetin guacyl in comparison with celecoxib in patients with rheumatoid arthritis. Jajić Z; Malaise M; Nekam K; Koó E; Dankó K; Kovacs M; Scarpignato C Clin Exp Rheumatol; 2005; 23(6):809-18. PubMed ID: 16396699 [TBL] [Abstract][Full Text] [Related]
65. COX-2-Specific inhibitors--the emergence of a new class of analgesic and anti-inflammatory drugs. Everts B; Währborg P; Hedner T Clin Rheumatol; 2000; 19(5):331-43. PubMed ID: 11055820 [TBL] [Abstract][Full Text] [Related]
66. Gastrointestinal and cardiovascular risk of non-selective NSAIDs and COX-2 inhibitors in elderly patients with knee osteoarthritis. Turajane T; Wongbunnak R; Patcharatrakul T; Ratansumawong K; Poigampetch Y; Songpatanasilp T J Med Assoc Thai; 2009 Dec; 92 Suppl 6():S19-26. PubMed ID: 20128070 [TBL] [Abstract][Full Text] [Related]
67. Rationale, design, and governance of Prospective Randomized Evaluation of Celecoxib Integrated Safety versus Ibuprofen Or Naproxen (PRECISION), a cardiovascular end point trial of nonsteroidal antiinflammatory agents in patients with arthritis. Becker MC; Wang TH; Wisniewski L; Wolski K; Libby P; Lüscher TF; Borer JS; Mascette AM; Husni ME; Solomon DH; Graham DY; Yeomans ND; Krum H; Ruschitzka F; Lincoff AM; Nissen SE; Am Heart J; 2009 Apr; 157(4):606-12. PubMed ID: 19332185 [TBL] [Abstract][Full Text] [Related]
68. Time variations in the risk of myocardial infarction among elderly users of COX-2 inhibitors. Lévesque LE; Brophy JM; Zhang B CMAJ; 2006 May; 174(11):1563-9. PubMed ID: 16670396 [TBL] [Abstract][Full Text] [Related]
69. Evaluation of risk profiles for gastrointestinal and cardiovascular adverse effects in nonselective NSAID and COX-2 inhibitor users: a cohort study using pharmacy dispensing data in The Netherlands. Layton D; Souverein PC; Heerdink ER; Shakir SA; Egberts AC Drug Saf; 2008; 31(2):143-58. PubMed ID: 18217790 [TBL] [Abstract][Full Text] [Related]
70. A cost-effectiveness analysis of celecoxib compared with diclofenac in the treatment of pain in osteoarthritis (OA) within the Swedish health system using an adaptation of the NICE OA model. Brereton N; Pennington B; Ekelund M; Akehurst R J Med Econ; 2014 Sep; 17(9):677-84. PubMed ID: 24914585 [TBL] [Abstract][Full Text] [Related]
72. [Clinical pharmacology of the selective COX-2 inhibitors]. Burian M; Geisslinger G Orthopade; 2003 Dec; 32(12):1078-87. PubMed ID: 14655004 [TBL] [Abstract][Full Text] [Related]
73. Review of the cardiovascular safety of COXIBs compared to NSAIDS. Moodley I Cardiovasc J Afr; 2008; 19(2):102-7. PubMed ID: 18516356 [TBL] [Abstract][Full Text] [Related]
74. Factors associated with celecoxib and rofecoxib utilization. Rawson NS; Nourjah P; Grosser SC; Graham DJ Ann Pharmacother; 2005 Apr; 39(4):597-602. PubMed ID: 15755796 [TBL] [Abstract][Full Text] [Related]
75. Cardiovascular thrombotic events in arthritis trials of the cyclooxygenase-2 inhibitor celecoxib. White WB; Faich G; Borer JS; Makuch RW Am J Cardiol; 2003 Aug; 92(4):411-8. PubMed ID: 12914871 [TBL] [Abstract][Full Text] [Related]
76. Risks and benefits of COX-2 inhibitors vs non-selective NSAIDs: does their cardiovascular risk exceed their gastrointestinal benefit? A retrospective cohort study. Rahme E; Nedjar H Rheumatology (Oxford); 2007 Mar; 46(3):435-8. PubMed ID: 17255138 [TBL] [Abstract][Full Text] [Related]
77. Efficacy and tolerability of celecoxib compared with diclofenac slow release in the treatment of acute ankle sprain in an Asian population. Nadarajah A; Abrahan L; Lau FL; Hwang LJ; Fakir-Bolte C Singapore Med J; 2006 Jun; 47(6):534-42. PubMed ID: 16752024 [TBL] [Abstract][Full Text] [Related]
78. Efficacy of intra-articular injection of celecoxib in a rabbit model of osteoarthritis. Jiang D; Zou J; Huang L; Shi Q; Zhu X; Wang G; Yang H Int J Mol Sci; 2010 Oct; 11(10):4106-13. PubMed ID: 21152323 [TBL] [Abstract][Full Text] [Related]
79. Celecoxib for the treatment of pain and inflammation: the preclinical and clinical results. Tindall E J Am Osteopath Assoc; 1999 Nov; 99(11 Suppl):S13-7. PubMed ID: 10643176 [TBL] [Abstract][Full Text] [Related]
80. COX-2 inhibitors celecoxib and parecoxib: valuable options for postoperative pain management. Gajraj NM Curr Top Med Chem; 2007; 7(3):235-49. PubMed ID: 17305567 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]